How to Value a Telehealth or Digital Health Company in 2026

Telehealth valuations have had one of the wildest rides in M&A history. In 2021, I watched digital health companies raise capital at 15-25x revenue. By late 2022, those same companies were trading at 2-4x — if they could raise at all. Now, in 2026, the market has settled into something rational. Telehealth is no longer a pandemic novelty — it's an established care delivery channel. And the valuation framework reflects that maturity.

The challenge is that "telehealth company" encompasses wildly different business models, from B2B infrastructure platforms to direct-to-consumer prescription mills. Each model has its own valuation logic. Let me break them down.

Three Models, Three Valuation Frameworks

B2B telehealth platforms— companies that sell telehealth infrastructure to health systems, employers, or payers — are valued like SaaS businesses because that's essentially what they are. Think Amwell, Teladoc's enterprise division, or specialty-specific platforms like Wheel or OpenLoop. These trade at 3-8x revenue, with the range determined by growth rate, net revenue retention, and gross margins. A platform growing 40%+ with 120%+ NRR commands 6-8x. One growing 15% with 95% NRR is worth 3-4x.

Direct-to-consumer telehealth— the Hims & Hers, Ro, Done model where consumers pay out-of-pocket for virtual visits and prescriptions — is valued on a blend of revenue multiples and unit economics. These companies trade at 2-5x revenue, but the variance comes from customer lifetime value (LTV), customer acquisition cost (CAC), and monthly retention. Hims traded at roughly 3x forward revenue through most of 2025. A smaller DTC telehealth startup with $5M in revenue, 70% gross margins, and 60% annual retention might be worth $10-20M (2-4x).

Telepsychiatry and telebehavioral healthcommands the highest multiples in the category — 8-12x EBITDA for established practices. The reason is simple supply-demand economics: the US has a severe shortage of psychiatrists and psychiatric nurse practitioners, and telehealth is the only scalable delivery model. Companies like Talkiatry, Cerebral (post-rebrand), and Iris Telehealth have attracted significant PE capital precisely because the provider shortage creates a durable competitive moat.

Key Metrics Buyers Scrutinize

Regardless of model, telehealth acquirers focus on metrics that are somewhat unique to the digital health space.

Monthly active patients (MAP).Not registered users — active patients who had at least one visit or filled a prescription in the trailing 30 days. A DTC company with 500K registered users but only 40K MAP has an engagement problem. Buyers value active patients at $200-800 each depending on specialty and LTV, but registered-only users are essentially worthless.

Visit completion rate. What percentage of scheduled appointments actually happen? Industry average is 85-90% for telehealth vs. 75-80% for in-person. Companies below 80% completion have a UX or workflow problem. Above 92% signals a well-designed patient experience.

Provider utilization. How many patient hours does each clinician deliver per week? A telepsychiatry platform where providers average 28-32 patient hours per week is well-optimized. Below 20 hours, the platform is over-staffed or has demand issues. This metric directly determines whether the company can deliver attractive provider economics while maintaining margins.

Patient retention/churn. Monthly churn rates in DTC telehealth typically run 5-10%, meaning you replace your entire patient base every 10-20 months. A company with 3% monthly churn (70% annual retention) is worth 2-3x more than one with 8% monthly churn (38% annual retention) because the LTV math is dramatically different. An average patient paying $85/month with 3% churn has an LTV of roughly $2,800. At 8% churn, that drops to $1,060.

State licensing coverage. Telehealth companies that can serve patients in 40+ states have a significant advantage over those limited to 10-15 states. Each new state requires provider licensing, regulatory compliance, and often specific telehealth consent procedures. Broader coverage = larger addressable market = higher multiple.

The Regulatory Factor

Telehealth valuation cannot be divorced from regulatory risk, and 2026 represents a pivotal moment. The Ryan Haight Act governs prescribing of controlled substances via telehealth, and DEA telehealth prescribing flexibilities — first granted during COVID and extended multiple times — remain subject to potential rulemaking changes.

Companies heavily dependent on telehealth prescribing of controlled substances (stimulants for ADHD, benzodiazepines, certain weight-loss medications) face meaningful regulatory risk. Done Health's DOJ investigation and Cerebral's compliance struggles demonstrated that this risk is not theoretical. Buyers discount these models by 20-40% compared to telehealth companies focused on non-controlled prescribing or therapy-only models.

Conversely, companies that have built compliance infrastructure — in-person visit requirements for controlled substances, robust prescription drug monitoring program (PDMP) integration, and state-by-state regulatory playbooks — trade at premiums because they've turned regulatory complexity into a moat.

Telepsychiatry: The Premium Segment

I want to spend extra time on behavioral health because it's where the strongest telehealth valuations live today. The US needs roughly 28,000 more psychiatrists than it currently has, according to HRSA projections. This shortage has persisted for decades and is getting worse as the existing psychiatrist workforce ages.

Telepsychiatry solves this by allowing psychiatrists and psychiatric NPs to see patients across state lines from anywhere. A single provider can serve patients in 10+ states from their home office. This leverage is what drives the premium multiples.

Telepsychiatry practices with $2M+ in revenue and 10+ providers consistently trade at 8-12x EBITDA. Key value drivers include: insurance credentialing breadth (practices paneled with 15+ major payers command premiums), average provider tenure (turnover is the biggest cost center), and the ratio of psychiatrists to NPs (mixed models with MD oversight of NPs scale better).

A telepsychiatry practice collecting $4M annually with 15 providers, $1.2M EBITDA, and 85% insurance-based revenue might sell for $10-14M (8-12x EBITDA) to a PE-backed behavioral health platform. That same practice, if entirely cash-pay and dependent on DTC marketing, might trade at $6-8M (5-7x EBITDA) because of the customer acquisition cost treadmill.

What's Changed Since the 2021 Peak

The rationalization from 2021 peak valuations has been severe but healthy. Companies that raised at 15-20x revenue have either grown into their valuations (the rare winners), restructured at dramatically lower valuations (most VC-backed companies), or shut down (Babylon Health, Pear Therapeutics, and others).

The surviving companies are generally better businesses. They've cut customer acquisition costs, improved unit economics, and in many cases pivoted from pure growth to profitability. For buyers in 2026, this means more realistic acquisition targets with cleaner financials and proven models — albeit at lower growth rates than the pandemic era.

A practical benchmark: profitable telehealth companies with $5-20M in revenue trade at 3-6x revenue or 8-15x EBITDA depending on growth and specialty. Pre-profit companies with strong unit economics trade at 2-4x revenue. Pre-profit companies with unproven unit economics trade at 1-2x revenue or struggle to find buyers at all.

The Bottom Line

Telehealth valuation in 2026 rewards substance over story. The market no longer pays for "total addressable market" slides and hockey-stick projections. It pays for retention, unit economics, and regulatory durability. Telepsychiatry and telebehavioral health command the highest multiples (8-12x EBITDA) because of structural provider shortages. B2B platforms trade like SaaS (3-8x revenue). DTC models are viable but need to prove they can retain patients profitably (2-5x revenue). The broader healthcare M&A market has moved past telehealth hype and into telehealth fundamentals — and that's actually a better environment for sellers with real businesses.